|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
ALK(-) CD30(+) anaplastic large cell lymphoma is a type of non-Hodgkin lymphoma showing poor prognosis, and seldom co-occurs with sarcoidosis.
|
30909793 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
High-CD30-expressing NHL patients (n=33) were enrolled except anaplastic large cell lymphoma.
|
31476851 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Systemic anaplastic large cell lymphoma (ALCL) is an aggressive CD30(+) non-Hodgkin lymphoma.
|
25869285 |
2015 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) is a subtype of non-Hodgkin lymphoma composed of CD30-positive cells and now recognized as three different entities: primary cutaneous ALCL, primary systemic anaplastic lymphoma kinase (ALK)-positive (ALK+) ALCL and primary ALK-negative (ALK-) ALCL.
|
24696735 |
2014 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this report, we demonstrate that 5-aza-CdR exhibits high antineoplastic activity against anaplastic large cell lymphoma (ALCL), a rare CD30 positive non-Hodgkin lymphoma of T-cell origin.
|
22687603 |
2012 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Chromosomal translocation t(2;5) and the resulting fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) are detected in 50% to 70% of anaplastic large cell lymphoma (ALCL), which is a T/null cell non-Hodgkin's lymphoma showing anaplastic morphology with cell surface expression of CD30.
|
16982741 |
2006 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic, CD30(+), large-cell lymphoma (ALCL) is a subtype of non-Hodgkin's lymphoma that accounts for 2% to 8% of all lymphomas.
|
10767704 |
2000 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
A recurrent, reciprocal balanced translocation, t(2;5) (p23;q35), has been recognized in CD30+ anaplastic large-cell lymphomas (ALCL), a newly recognized subtype comprising approximately 5% of all non-Hodgkin's lymphoma (NHL).
|
9684923 |
1998 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Analysis of the human and mouse promoter region of the non-Hodgkin's lymphoma-associated CD30 gene.
|
9858312 |
1998 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The authors studied cytogenetically a case of CD30+ anaplastic large cell non-Hodgkin lymphoma previously diagnosed as malignant histiocytosis and detected a translocation involving chromosomes 1 and 5, t(1;5)(q32:q35).
|
8616796 |
1996 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mycosis fungoides, lymphoblastic, and CD30-positive anaplastic large T-cell NHL cases were consistently EBV-negative.
|
8562929 |
1996 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) is a subtype of non-Hodgkin's lymphoma (NHL) involving large CD30+ neoplastic cells, which occasionally carries the chromosomal translocation t(2;5)(p23;q35).
|
9021682 |
1996 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) is a subtype of non-Hodgkin's lymphoma characterized by the CD30+ large neoplastic cells and sometimes carries a t(2;5)(p23;q35).
|
7655022 |
1995 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) expressing the CD30 antigen is an uncommon subtype of non-Hodgkin's lymphoma characterized by distinct morphological and clinical features.
|
7564510 |
1995 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these data suggest that the CD30L-CD30 interaction has potent biological activity and might play a critical role in the immune response and pathogenesis of HD and some NHL, in particular Burkitt lymphomas.
|
7528856 |
1994 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Anaplastic large-cell lymphoma (ALCL) represents a morphologically distinct type of non-Hodgkin's lymphoma (NHL) characterized phenotypically by the expression of the CD30 antigen, a new member of the nerve growth factor gene family.
|
8204884 |
1994 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
A novel association, Epstein-Barr virus-positive Ki-1+/CD30+ anaplastic large cell non-Hodgkin's lymphoma of B-cell phenotype in immunosuppressed renal transplant recipients is reported.
|
1326891 |
1992 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ki-1 (CD30)-positive, large-cell anaplastic lymphoma (LCAL) is a distinctive subset of non-Hodgkin's lymphoma; morphologically, the neoplastic cells of LCAL may closely resemble Reed-Sternberg cell variants of Hodgkin's disease.
|
1323222 |
1992 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Morphology in Ki-1(CD30)-positive non-Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5)(p23;q35).
|
2157342 |
1990 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene.
|
3260522 |
1988 |